169 related articles for article (PubMed ID: 22179104)
1. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
[TBL] [Abstract][Full Text] [Related]
3. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Houk BE; Bello CL; Kang D; Amantea M
Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Lankheet NA; Kloth JS; Gadellaa-van Hooijdonk CG; Cirkel GA; Mathijssen RH; Lolkema MP; Schellens JH; Voest EE; Sleijfer S; de Jonge MJ; Haanen JB; Beijnen JH; Huitema AD; Steeghs N
Br J Cancer; 2014 May; 110(10):2441-9. PubMed ID: 24736581
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
[TBL] [Abstract][Full Text] [Related]
11. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Boven E; Massard C; Armand JP; Tillier C; Hartog V; Brega NM; Countouriotis AM; Ruiz-Garcia A; Soria JC
Br J Cancer; 2010 Sep; 103(7):993-1000. PubMed ID: 20717111
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
[TBL] [Abstract][Full Text] [Related]
13. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
[TBL] [Abstract][Full Text] [Related]
14. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Lankheet NA; Blank CU; Mallo H; Adriaansz S; Rosing H; Schellens JH; Huitema AD; Beijnen JH
J Anal Toxicol; 2011 Oct; 35(8):558-65. PubMed ID: 22004675
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
[TBL] [Abstract][Full Text] [Related]
16. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
Rudek MA; Moore PC; Mitsuyasu RT; Dezube BJ; Aboulafia D; Gerecitano J; Sullivan R; Cianfrocca ME; Henry DH; Ratner L; Haigentz M; Dowlati A; Little RF; Ivy SP; Deeken JF
Cancer; 2014 Apr; 120(8):1194-202. PubMed ID: 24474568
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Faivre S; Delbaldo C; Vera K; Robert C; Lozahic S; Lassau N; Bello C; Deprimo S; Brega N; Massimini G; Armand JP; Scigalla P; Raymond E
J Clin Oncol; 2006 Jan; 24(1):25-35. PubMed ID: 16314617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
